These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aromatase and breast cancer. Brodie A; Sabnis G; Jelovac D J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978 [TBL] [Abstract][Full Text] [Related]
3. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model. Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543 [TBL] [Abstract][Full Text] [Related]
4. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587 [TBL] [Abstract][Full Text] [Related]
5. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349 [TBL] [Abstract][Full Text] [Related]
6. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor. Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181 [TBL] [Abstract][Full Text] [Related]
7. Model systems: mechanisms involved in the loss of sensitivity to letrozole. Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659 [TBL] [Abstract][Full Text] [Related]
8. Development and mechanistic insight into enhanced cytotoxic potential of hyaluronic acid conjugated nanoparticles in CD44 overexpressing cancer cells. Saneja A; Nayak D; Srinivas M; Kumar A; Khare V; Katoch A; Goswami A; Vishwakarma RA; Sawant SD; Gupta PN Eur J Pharm Sci; 2017 Jan; 97():79-91. PubMed ID: 27989859 [TBL] [Abstract][Full Text] [Related]
10. Stopping treatment can reverse acquired resistance to letrozole. Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495 [TBL] [Abstract][Full Text] [Related]
11. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Long BJ; Jelovac D; Thiantanawat A; Brodie AM Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443 [TBL] [Abstract][Full Text] [Related]
12. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Belosay A; Brodie AM; Njar VC Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897 [TBL] [Abstract][Full Text] [Related]
13. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. Kijima I; Itoh T; Chen S J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272 [TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810 [TBL] [Abstract][Full Text] [Related]
15. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560 [TBL] [Abstract][Full Text] [Related]
16. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Sabnis G; Brodie A Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251 [TBL] [Abstract][Full Text] [Related]
17. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492 [TBL] [Abstract][Full Text] [Related]
18. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593 [TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin. Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431 [TBL] [Abstract][Full Text] [Related]
20. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model]. Chen HY; Liu ZH Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]